Guggenheim analyst Subbu Nambi reiterated a Buy rating on Illumina yesterday and set a price target of $170.00. The company’s shares closed yesterday at $133.61.
About Solid Biosciences Solid Biosciences is a precision genetic medicine company focused on advancing a portfolio of gene therapy candidates targeting rare neuromuscular and cardiac diseases, ...
Core Bond Fund returned 1.00% in Q4, trailing its benchmark. Read our full analysis of market trends and economic projections ...
SAN CARLOS, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced that Company management will participate in a fireside ...
In addition to Guggenheim, Merck & Company also received a Buy from Bank of America Securities’s Jason Gerberry in a report issued yesterday. However, on February 4, Bernstein maintained a Hold rating ...
InvestorsHub on MSN
Avalo Therapeutics shares jump as Guggenheim starts coverage with buy
Shares of Avalo Therapeutics Inc (NASDAQ:AVTX) climbed about 5.8% in premarket trading on Monday after Guggenheim launched ...
GE Vernova upgraded to Buy at Guggenheim, which thinks the market still may underestimate the company's potential for cash ...
There’s good news on the horizon for design fans: the long-awaited Guggenheim Museum in Abu Dhabi looks all set to open in 2025. With legendary architect and design extraordinaire Frank Gehry at the ...
The Guggenheim announced plans for its U.A.E. location back in 2006. Rendering of the Frank Gehry-designed Guggenheim Abu Dhabi. Photo courtesy Tourism Development and Investment Company and Gehry ...
GULF and the Illuminator, action at the Guggenheim Museum (2016) (All photos by the author for Hyperallergic) Last night, in a visually dazzling act of public protest, the artist-activist groups ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results